Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly Temozolomide

NCT04677049 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT04677049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04677049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of Niacin in Patients With Newly Diagnosed Glioblastoma Receiving Concurrent Radiotherapy and Temozolomide Followed by Monthly Temozolomide
Lead sponsor
AHS Cancer Control Alberta
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 18, 2021
Completion date
December 31, 2027
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma idh (isocitrate dehydrogenase) wildtype